By Andrew W. Lo
FORTUNE – What if I told you about an investment fund that diversifies your portfolio, shields you from fluctuations in the stock market, and earns double-digit returns? Sounds interesting, right?
Did I mention that this investment also creates potentially life-saving treatments for deadly rare diseases?
This fund doesn't exist -- at least not yet. I'm cautiously optimistic, however, that in the near future we'll see the launch of an orphan disease "mega-fund" that finances early-stage biomedical research and drug development and is also a tidy investment.
It works like this: The fund pools a large number of drug development efforts into a single financial entity or "mega-fund." With the lower risk that comes from investing in multiple drug trials simultaneously, the fund yields a more attractive risk-adjusted return on the investment and a higher likelihood of success in finding cures for diseases. This, in turn, enables the fund to raise money by issuing "research-backed obligations" or RBOs, bonds guaranteed by the portfolio of possible drugs and their associated intellectual property. Because RBOs are structured as bonds, they appeal to fixed-income investors, who collectively represent a much larger pool of capital and who have traditionally not been able to participate in investments in early-stage drug development.
This fund needn't be big. In fact, in some recent research, my co-authors and I found that a fund of only $575 million may yield double-digit expected rates of return with only 10 to 20 projects in the portfolio. Admittedly, half a billion dollars isn't chump change, but it's not a lot of money in the world of pension funds, hedge funds, and other institutional investors. And at a time of historically low interest rates, this fund represents a practical investment that's not very highly associated with the stock market and that is capable of generating attractive returns.
So why now? A little background: Orphan diseases -- which are defined by the Orphan Drug Act of 1983 (ODA) as illnesses that affect fewer than 200,000 people in the U.S. -- were once anathema to the pharmaceutical industry. Drug companies thought it was a waste of time to develop drugs for such a small patient population; there simply wasn't enough money there.
Today, things are different. This once-neglected category of diseases, which includes cystic fibrosis, Duchenne muscular dystrophy, and amyotrophic lateral sclerosis (more commonly known as Lou Gehrig's disease), commands a market worth nearly $90 billion a year. What's more, rare diseases aren't as rare as we may think. They're believed to affect more than twice the number of all U.S. cancer patients! At least 25 million Americans are afflicted with one of almost 7,000 orphan diseases.
What has also changed is that we're now better at treating orphan diseases. A combination of technological advances pioneered by scientists, biotech entrepreneurs, big pharma, and key insights from the Human Genome Project now allows us to identify the underlying causes of many of these disorders. And because these diseases afflict a narrow range of individuals, their mutations have similar pathologies and are therefore simpler to pinpoint. No longer are you looking for a needle in a haystack, you're looking for a needle in a basket of straw.
For a number of reasons, orphan drugs are particularly well suited to portfolio financing: Because of the unique pathological characteristics of these diseases, as well as the considerable support provided by the ODA, orphan drugs have higher success rates and shorter development times, but are still capable of generating lifetime revenues comparable to non-orphan drugs. In fact, a typical orphan drug can be expected to attain sales of $100 to $500 million per year, according to Thomson Reuters. Finally, the ODA provides a number of incentives to orphan drug developers including tax credits, expedited U.S. Food and Drug Administration review, and longer periods of patent protection. One analysis found that its impact extended the average combined patent/exclusivity period by nearly a year, resulting in an average competition-free marketing period of 11.7 years.
An orphan disease mega-fund is not only a potentially attractive investment; it's also a potential lifesaver. The drug development process has become expensive, lengthy, and risky -- and not just for orphan diseases. The biotech and pharmaceutical sectors have performed miserably over the past decade, which has caused venture capital flows to wane. At the same time, government funding -- another important source of funding for biomedical research -- has been declining. In other words, this is an area desperate for funding, and a mega-fund would bring much-needed resources to drug discovery.
The fund also has appeal to philanthropists and patient advocacy groups because they can put their dollars to work in a new way -- by providing financial guarantees to mega-fund securities. The impact of such guarantees is to reduce the risk of the mega-fund, greatly expanding their appeal to a broader audience of potential investors, giving philanthropists just what want: impact.
Finance doesn't have to be a zero-sum game. With sufficient scale and proper financial engineering, you can actually do well by doing good.
Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management and director of the MIT Laboratory for Financial Engineering.
Can ordinary investors really make money through good times and bad? A review of The Indomitable Investor, by Steven Sears.
By Scott Cendrowski, writer-reporter
FORTUNE -- Let's say you've never read a book on investing. You avoided Peter Lynch's advice on how to get one up on Wall Street, dodged all the Internet get-rich-quick schemes, brushed off your in-laws' efforts to get you to read Suze Orman, and finally steered MOREMay 4, 2012 6:57 AM ET
Want to know what Warren Buffett's buying? Or any other major stock player? One small investor has a site for you.
By Scott Cendrowski, reporter
FORTUNE -- Like many people, Charlie Tian loaded up on tech stocks in the '90s. A scientist at Fujitsu, he thought he knew the sector. Then the market crash proved he didn't. Tian, 43, figured there was a better way for small investors. He started reading Warren MOREAug 16, 2011 5:00 AM ET
The solar panel-maker's stock has flamed out over the last two years. Is that about to change?
By Scott Cendrowski, writer-reporter
FORTUNE -- The darling of the solar panel industry has been stuck in the mud. First Solar earned the respect of investors as the world's lowest-cost maker of solar panel systems soon after its 2006 IPO. The stock later roared past $300. Then worries of Chinese competition and 2008's market collapse MOREAug 10, 2011 5:00 AM ET
Delaware Dividend Income Fund co-manager Nik Lalvani says the beaten-down defense contractor is ready to launch.
By Scott Medintz, contributor
FORTUNE -- The Delaware Dividend Income Fund (DDIAX) is idiosyncratic, mixing large-cap dividend stocks with REITs and convertible and high-yield bonds to earn an average of 6.1% annually over 10 years. Today, says co-manager Nik Lalvani, 36, "we think the best equity-like returns are actually in equities." After all, the U.S. stock MOREJul 12, 2011 5:00 AM ET
Editor's Note: Every Sunday, Fortune publishes a favorite story from our archive. As controversy swirls around whether Fed Chair Ben Bernanke is downplaying inflation predictions, we turn back to May 1977 for timely advice from Warren Buffett. The Oracle of Omaha has clashed with Bernanke over inflation time and time again, and here Buffett warns how rising prices can hamper growth "not because the market falls, but in spite of MOREJun 12, 2011 9:15 AM ET
No one knows exactly where gold came from, but one theory posits it was forged in collapsing stars, traveling millions of light-years before becoming part of the earth's formation. So far we've mined 166,600 tons of the metal, more than half of all recoverable gold. Gold doesn't generate earnings and its price is volatile, but as an inflation hedge it holds appeal. --Tara Moore
Sources: World Gold Council (including the prices MOREJun 6, 2011 5:00 AM ET
In a post-recession world, you need serious experience to guide your portfolio. So we sat down with five pros who have the right guidance for these troubled times.
Roundtable interview by Geoff Colvin, senior editor at large
THE LINEUP: Renée Haugerud Galtere Ltd. Wally Weitz Weitz Funds Abhay Deshpande First Eagle Investment Management James Swanson MFS Investment Management Dave Ellison FBR Fund Advisors
The financial crisis is over -- right? Just one problem: The markets haven't settled down, and investing hasn't become any MOREDec 13, 2010 3:00 AM ET
|AT&T cuts prices again|
|Asian stocks slump after plane vanishes|
|Ukraine crisis: Aid, sanctions and fallout|
|Can Fox's reboot of 'Cosmos' find an audience?|
|Winners and losers of the bull market|